发明名称 Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof
摘要 The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.
申请公布号 US2016031965(A1) 申请公布日期 2016.02.04
申请号 US201514883203 申请日期 2015.10.14
申请人 BioMarin Pharmaceutical Inc. 发明人 Aoyagi-Scharber Mika;Christianson Teresa Margaret;Dvorak-Ewell Melita;Wendt Daniel J.;Long Shinong;LeBowitz Jonathan;Gold Daniel Solomon
分类号 C07K14/65;C12N9/24 主分类号 C07K14/65
代理机构 代理人
主权项 1. A targeted therapeutic fusion protein comprising (a) a lysosomal enzyme, (b) a peptide tag having an amino acid sequence at least 70% identical to amino acids 8-67 of mature human IGF-II and (c) a spacer peptide between the lysosomal enzyme and the IGF-II peptide tag, wherein the spacer peptide comprises the amino acid sequence set out in SEQ ID NO: 55.
地址 Novato CA US